RepliCel Life Sciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RP.V research report →
Companywww.replicel.com
RepliCel Life Sciences Inc. , a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory.
- CEO
- Andrew Schutte
- IPO
- 2014
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $1.10M
- P/E
- -9.60
- P/S
- 3.12
- P/B
- -0.21
- EV/EBITDA
- -5.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -101.77%
- Net Margin
- -27.50%
- ROE
- 1.86%
- ROIC
- 49.90%
Growth & Income
- Revenue
- $353.74K · 0.00%
- Net Income
- $-97,291 · 68.82%
- EPS
- $-0.00 · 69.81%
- Op Income
- $-360,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.04
- Beta
- 1.02
- Avg Volume
- 29.65K
Get TickerSpark's AI analysis on RP.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RP.V Coverage
We haven't published any research on RP.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RP.V Report →